Effects of ulinastatin, an antiprotease, on alloxan-induced lung injury in dogs.
To determine if alloxan-induced lung injury could be prevented by an antiprotease, ulinastatin, we used three groups of five anesthetized, ventilated dogs. They were given saline (20 ml/kg/hr) infusion alone (saline group), alloxan (75 mg/kg) + saline infusion (alloxan group), or ulinastatin (50,000 U/kg) + alloxan + saline infusion (ulinastatin group). The course of all dogs was followed for three hours. In the saline group, extravascular lung water to blood-free dry weight (Qwl/dQl) was 3.22 +/- 0.31 g/g (mean +/- SE). The alloxan group presented the following significant findings: a decrease in white blood cell and platelet counts (44.2% and 68.2% of control, respectively) at five minutes; an increase in thromboxane B2 and 6-keto-prostaglandin F1 alpha (731.6% and 476.6% of control, respectively) at 15 minutes; an increase in beta-glucuronidase (124.8% of control) at 30 minutes; and an increase in Qwl/dQl (8.84 +/- 1.82 g/g) at the end of experiment. The addition of ulinastatin significantly reduced most alloxan-induced effects: differences in white blood cell counts, thromboxane B2, 6-keto-prostaglandin F1 alpha, and Qwl/dQl between the saline and ulinastatin groups were small. We conclude that ulinastatin significantly reduces the extent of lung water accumulation in alloxan-induced lung injury.
Arakawa
M
M
Second Department of Internal Medicine, Gifu University School of Medicine, Japan.
Kambara
K
K
Miyazaki
H
H
Segawa
T
T
Ando
F
F
Kawada
T
T
Ohno
M
M
Nakahara
K
K
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000496:Alloxan / Q000037:antagonists & inhibitors; D000818:Animals; D004285:Dogs; D005966:Glucuronidase / Q000097:blood; D006023:Glycoproteins / Q000494:pharmacology*; D007958:Leukocyte Count / Q000187:drug effects; D010976:Platelet Count / Q000187:drug effects; D011654:Pulmonary Edema / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D013929:Thromboxane B2 / Q000097:blood; D014361:Trypsin Inhibitors / Q000494:pharmacology*
D006023:Glycoproteins; D014361:Trypsin Inhibitors; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D000496:Alloxan; D005966:Glucuronidase; C028665:urinastatin